Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 4/20 | 0.36 |
| ▸ | MMP7 | P09237 | 4/20 | 0.36 |
| ▸ | MMP12 | P39900 | 4/20 | 0.36 |
| ▸ | MMP13 | P45452 | 4/20 | 0.36 |
| ▸ | ECE1 | P42892 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 7/20 | 0.33 |
| ▸ | CA1 | P00915 | 5/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 4/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27951234 | 0.82 | CA2 (0.41) | TP53CA2CA1TDP1CA9 | |
| SCHEMBL9634438 | 0.80 | TSHR (0.41) | TP53CA2CA1TSHRDNM1 | |
| SCHEMBL6929306 | 0.78 | FAAH (0.36) | MMP1MMP7MMP12MMP13ECE1 | |
| SCHEMBL9150270 | 0.76 | APP (0.32) | TP53TSHRSMN1; SMN2MAPK1 | |
| SCHEMBL27289489 | 0.75 | TP53 (0.37) | MMP1MMP7MMP12MMP13ECE1 | |
| SCHEMBL10770770 | 0.75 | TP53 (0.46) | TP53CA2CA1FDPSCA9 | |
| SCHEMBL11046101 | 0.74 | TP53 (0.33) | MMP1MMP7MMP12MMP13ECE1 | |
| SCHEMBL11415703 | 0.74 | TP53 (0.47) | TP53CA2CA1FDPS | |
| SCHEMBL28274457 | 0.71 | TP53 (0.43) | TP53CA2CA1FDPSCA9 | |
| SCHEMBL14892962 | 0.71 | TP53 (0.43) | TP53CA2CA1DNM1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7939520-B2 | Aminoazacyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | WYETH LLC (US) | 2011-05-10 | — | — | US | disclosed |
| EP-2158195-A1 | 5- (AMINOAZACYCLYL) -3-SULFONYL-LH- INDAZOLES AS 5-HYDROXYTRYPTAMINE- 6 LIGANDS FOR THE TREATMENT OF CNS DISORDERS | Wyeth LLC (US) | 2010-03-03 | — | — | EP | disclosed |
| US-20090253711-A1 | HETEROCYCLYL-3-SULFONYLINDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2009-10-08 | — | — | US | disclosed |
| US-7560470-B2 | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-07-14 | — | — | US | disclosed |
| US-20080293688-A1 | AMINOAZACYCLYL-3-SULFONYLINDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| WO-2008144299-A1 | 5- (AMINOAZACYCLYL) -3-SULFONYL-LH- INDAZOLES AS 5-HYDROXYTRYPTAMINE- 6 LIGANDS FOR THE TREATMENT OF CNS DISORDERS | WYETH (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20070232618-A1 | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-10-04 | — | — | US | disclosed |
| US-7238696-B2 | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-07-03 | — | — | US | disclosed |
| EP-1592683-A2 | HETEROCYCLYL-3-SULFONYLINDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004074243-A2 | HETEROCYCLYL-3-SULFONYLINDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20040167122-A1 | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | WYETH | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232618-A1 | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | HTR6, HTR2C, HTR3B | MMP1 4726/4885MMP7 3701/4885MMP12 4749/4885 |
| US-20090253711-A1 | HETEROCYCLYL-3-SULFONYLINDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | HTR6, HTR2C, HTR3B | MMP1 4726/4885MMP7 3701/4885MMP12 4749/4885 |
| US-20080293688-A1 | AMINOAZACYCLYL-3-SULFONYLINDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | HTR6, HTR3B, HTR5A | MMP1 4550/4885MMP7 3668/4885MMP12 4648/4885 |
| US-20040167122-A1 | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | HTR6, HTR1A, HTR2C | MMP1 4599/4885MMP7 3855/4885MMP12 4774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.